Skip to main content

Advertisement

Table 2 Comparison of the final participant group with all other non-participants.

From: Recruitment of representative samples for low incidence cancer populations: Do registries deliver?

  Demographics of survivors
  Stage 1 (n = 468) Stage 2 (n = 232) Stage 3 (n = 64) Total (n = 468)
  Clinician did not consent (n = 102) Unable to contact clinician (n = 134) Survivor did not consent (n = 18) Unable to contact survivor (n = 150) Survivor did not consent (n = 20) Unable to contact survivor (n = 12) Did not consent and unable to contact (n = 436) Final participant group (n = 32)
  n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Age at diagnosis        
14-15 27 (26) 30 (22) 9 (50) 40 (27) 2 (10) 2 (17) 110 (25)* 11 (34)
16-17 27 (26) 51 (38) 2 (11) 46 (31) 8 (40) 6 (50) 140 (32) 16 (50)
18-19 48 (47) 53 (40) 7 (39) 64 (43) 10 (50) 4 (33) 186 (43)* 5 (16)
Gender         
Female 44 (43) 59 (44) 7 (39) 68 (45) 4 (20) 8 (67) 190 (44) 17 (53)
Male 58 (57) 75 (56) 11 (61) 82 (55) 16(80) 4 (33) 246 (56) 15 (47)
Cancer type        
Lymphoma 16 (16) 36 (27) 5 (28) 36 (24) 4 (20) 2 (17) 99 (23) 6 (19)
Skin 25 (25) 21 (16) 3 (17) 31 (21) 2 (10) 2 (17) 84 (19) 2 (6.2)
Testicular 9 (8.8) 13 (9.7) 0 (0) 13 (8.6) 4 (20) 0 (0) 39 (8.9) 1 (3.1)
Thyroid 11 (11) 7 (5.2) 0 (0) 11 (7.3) 2 (10) 1 (8.3) 32 (7.3) 3 (9.3)
Leukaemia 13 (13) 17 (13) 3 (17) 21 (14) 2 (10) 2 (17) 58 (13) 8 (25)
Other** 28 (27) 40 (30) 7 (39) 38 (25) 6 (30) 5 (42) 124 (28) 12 (38)
  1. *Due to discrepancies in notified dates of diagnosis one non-participant may have been under 14 years of age and six non-participants may have been over 19 years of age at diagnosis.
  2. **"Other" includes cancers of brain, bone, connective tissue, colorectum, small intestine, kidney, liver, ovary, bladder, breast, lung and heart.